Profile data is unavailable for this security.
About the company
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product, NNZ-2591, is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.
- Revenue in AUD (TTM)228.67m
- Net income in AUD149.06m
- Incorporated2001
- Employees--
- LocationNeuren Pharmaceuticals LtdSuite 1.01117 Camberwell Road, Hawthorn EastMELBOURNE 3123AustraliaAUS
- Phone+61 39092-0480
- Websitehttps://www.neurenpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CStone Pharmaceuticals | 41.47m | -77.23m | 1.58bn | 93.00 | -- | 22.64 | -- | 38.10 | -0.3277 | -0.3277 | 0.177 | 0.2615 | 0.1487 | 1.38 | 1.68 | 1,698,809.00 | -27.69 | -39.13 | -54.45 | -60.19 | -12.18 | 66.69 | -186.23 | -170.86 | 1.20 | -29.83 | 0.554 | -- | -12.21 | -- | 75.16 | -- | -- | -- |
| Cisen Pharmaceutical Co Ltd | 728.97m | 100.82m | 1.59bn | 3.30k | 15.81 | 1.26 | -- | 2.18 | 1.08 | 1.08 | 7.84 | 13.59 | 0.472 | 2.10 | 5.34 | 1,079,074.00 | 6.58 | 6.51 | 8.12 | 8.07 | 53.70 | 55.92 | 13.94 | 10.84 | 3.48 | -- | 0.0069 | 37.16 | -10.77 | -0.6464 | -2.38 | -0.2215 | -0.3051 | 10.42 |
| SSY Group Ltd | 828.51m | 119.16m | 1.59bn | 5.70k | 13.59 | 1.23 | 7.82 | 1.92 | 0.223 | 0.223 | 1.55 | 2.46 | 0.3616 | 2.27 | 2.11 | 751,065.60 | 5.27 | 9.41 | 6.34 | 12.43 | 42.68 | 56.47 | 14.58 | 17.65 | 2.40 | 14.91 | 0.346 | 42.91 | -10.67 | 4.49 | -19.53 | -1.36 | -8.36 | 9.73 |
| Xeris Biopharma Holdings Inc | 376.17m | -22.11m | 1.60bn | 394.00 | -- | -- | -- | 4.25 | -0.1033 | -0.1033 | 1.67 | -0.0052 | 0.77 | 0.7301 | 5.61 | 675,474.60 | -4.52 | -31.61 | -6.46 | -42.28 | 84.56 | 79.76 | -5.88 | -77.77 | 1.35 | 0.3853 | 1.00 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| China Animal Husbandry Industry Co., Ltd | 1.29bn | 43.87m | 1.60bn | 4.30k | 36.52 | 1.37 | -- | 1.25 | 0.21 | 0.21 | 6.15 | 5.60 | 0.6863 | 5.30 | 4.19 | 1,461,064.00 | 2.32 | 5.25 | 3.37 | 7.48 | 15.59 | 22.15 | 3.38 | 7.31 | 1.62 | -- | 0.1625 | 31.16 | 11.30 | 7.79 | -82.41 | -22.24 | -0.0699 | -21.83 |
| Polypeptide Group AG | 621.31m | -58.21m | 1.61bn | 1.37k | -- | 2.89 | -- | 2.59 | -0.9494 | -0.9494 | 10.09 | 9.14 | 0.5153 | 2.06 | 6.35 | 261,379.80 | -4.83 | 0.555 | -6.57 | 0.7099 | 11.63 | 19.25 | -9.37 | 1.05 | 0.8234 | -0.1909 | 0.2517 | 62.37 | 4.28 | 10.70 | 61.97 | -- | 34.57 | -- |
| Neuren Pharmaceuticals Ltd | 228.67m | 149.06m | 1.61bn | -- | 11.17 | 4.91 | 10.83 | 7.06 | 1.14 | 1.14 | 1.76 | 2.60 | 0.8175 | -- | 12.92 | -- | 53.29 | 49.68 | 54.95 | 56.56 | -- | -- | 65.19 | 58.60 | -- | 63.36 | 0.00 | 0.00 | -5.63 | 202.59 | -9.57 | -- | -3.58 | -- |
| BioGaia AB | 243.66m | 52.71m | 1.62bn | 242.00 | 31.53 | 7.98 | 28.58 | 6.64 | 3.29 | 3.29 | 15.21 | 12.99 | 0.847 | -- | -- | 6,356,066.00 | 18.32 | 15.48 | 20.63 | 16.86 | 73.37 | 73.12 | 21.63 | 26.35 | -- | -- | -- | 133.18 | 8.11 | 15.54 | -5.30 | 13.11 | -25.87 | 24.01 |
| Zhejiang Ausun Pharmaceutical Co Ltd | 153.67m | 37.82m | 1.63bn | 1.22k | 42.83 | 3.40 | -- | 10.61 | 0.2241 | 0.2241 | 0.8963 | 2.83 | 0.2472 | 0.9248 | 3.00 | 616,180.10 | 6.08 | 8.91 | 7.77 | 12.10 | 51.51 | 53.44 | 24.61 | 27.68 | 2.17 | -- | 0.1383 | 27.35 | -2.63 | 20.90 | -18.55 | 29.68 | 17.53 | 43.79 |
| Day One Biopharmaceuticals Inc | 188.94m | -214.50m | 1.65bn | 184.00 | -- | 2.58 | -- | 8.72 | -1.48 | -1.48 | 1.30 | 4.39 | 0.2399 | 2.88 | 10.53 | 738,519.30 | -27.23 | -39.78 | -29.80 | -43.02 | 89.44 | -- | -113.53 | -414.14 | 8.55 | -- | 0.00 | -- | -- | -- | 49.45 | -- | -- | -- |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 468.94m | -74.38m | 1.65bn | 2.97k | -- | 1.39 | -- | 3.51 | -0.1112 | -0.1112 | 0.7189 | 1.82 | 0.204 | 2.09 | 3.30 | 771,487.60 | -4.90 | -0.1745 | -7.79 | -0.2739 | 34.13 | 64.36 | -24.05 | -0.6631 | 2.01 | -5.26 | 0.2563 | 69.54 | -26.67 | -9.85 | -547.14 | -- | 4.41 | -- |
| Changchun BCHT Biotechnology Co | 138.61m | -34.89m | 1.65bn | 1.27k | -- | 2.04 | -- | 11.92 | -0.4124 | -0.4124 | 1.64 | 9.57 | 0.1288 | 0.7183 | 0.4756 | 531,801.10 | -3.24 | 8.14 | -4.12 | 10.19 | 77.22 | 85.58 | -25.17 | 23.29 | 1.20 | -8.89 | 0.0696 | 14.91 | -32.64 | 4.73 | -53.67 | 0.9824 | 33.40 | -- |
Data as of Feb 16 2026. Currency figures normalised to Neuren Pharmaceuticals Ltd's reporting currency: Australian Dollar AUD
15.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| State Street Global Advisors, Australia, Ltd.as of 01 May 2025 | 5.34m | 4.22% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 4.03m | 3.18% |
| Vanguard Investments Australia Ltd.as of 31 Dec 2025 | 2.48m | 1.96% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 1.87m | 1.47% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 1.76m | 1.39% |
| BetaShares Capital Ltd.as of 30 Jan 2026 | 1.65m | 1.31% |
| State Street Global Advisors Trust Co.as of 01 May 2025 | 808.58k | 0.64% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 721.06k | 0.57% |
| DFA Australia Ltd.as of 31 Dec 2025 | 706.43k | 0.56% |
| Netwealth Investments Ltd.as of 14 Mar 2025 | 560.07k | 0.44% |
More ▼
Data from 31 Dec 2025 - 13 Feb 2026Source: FactSet Research Systems Inc.
